The past, present and future of antimycotic combination therapy.
about
[Clotrimazole and ciclopirox olamine respectively in combination with methylprednisolone aceponate as extemporaneous formulations].In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.Rationale for combination antifungal therapy.A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America.Pharmacotherapy of Candida bloodstream infections: new treatment options, new era.Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.British Association of Dermatologists' guidelines for the management of onychomycosis 2014.Drug synergies and the potential for combination therapy in onychomycosis.Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis.Antifungal chemotherapeutics.Pharmacotherapy of onychomycosis.In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methodsIn vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreusOnychomycosis: beyond cosmetic distress.Emerging therapeutic agents for onychomycosis.Optimizing efficacy of Amphotericin B through nanomodification.An update on treatment of onychomycosis.Synthesis, bioevaluation and structural study of substituted phthalazin-1(2H)-ones acting as antifungal agents.In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach.In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models.A new series of antibacterial nitrosopyrimidines: synthesis and structure-activity relationship.Synthesis, anticandidal activity and cytotoxicity of some tetrazole derivatives.Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.Preparation of some pyrazoline derivatives and evaluation of their antifungal activities.Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.Erythromycin, an inhibitor of mitoribosomal protein biosynthesis, alters the amphotericin B susceptibility of Candida albicans.Effects of several antifungal drug combinations against clinical and environmental isolates of Cryptococcus neoformans from China.Synthesis and antifungal activity of new hydrazide derivatives.Ring-substituted 4-hydroxy-1H-quinolin-2-ones: preparation and biological activity.Synthesis of some heterofunctionalized penicillanic acid derivatives and investigation of their biological activities.Aspergilli Response to Benzalkonium Chloride and Novel-Synthesized Fullerenol/Benzalkonium Chloride Nanocomposite.
P2860
Q30313543-6C80F7D9-3FF7-4E4E-A48F-6DF7CA2C919EQ34110440-A9AE4030-F9ED-42DD-B679-AD42E897A620Q34143326-3515F0D7-80A0-4F0F-8560-F0CC6FC167C4Q34335236-2D9DDCBF-4119-4C27-8A3F-8BDA1D63B389Q34335250-67037E9A-D9DC-44FE-B783-905D14596090Q34768471-47E6155D-B515-4751-AC6C-52F1861DC2A4Q34932922-4134F39E-D281-4162-9E04-380D99895B1FQ35437556-9A334EB6-5B0A-416F-B51B-A7374819DD73Q35544205-511A4244-A0FC-434F-9695-6F6DF82AEC7BQ36008679-55C2CE07-CB03-46B5-96EC-797BD0FEDC3CQ36018571-EFBEE926-5F46-44C5-962D-7EB28D5F8F66Q36111677-5D199E26-A780-4D9D-85D3-FDAC1325B7A6Q36150713-4F38C45E-CE43-4031-9278-B07541E04650Q36425093-CFB2517E-0B7E-48EC-B632-1C70131BC7EAQ36492208-174C3B6E-F6BE-4F00-A22F-57220C48EF3BQ36686125-48D8206B-C84A-4405-AB04-FE53AFCEF2C4Q36943999-9FED144B-F6DD-4D6E-80B8-00982AFB9630Q37178176-3679B6A9-4C26-4592-86EF-D02DC812C844Q38006059-91A17871-F537-4A10-846A-0FB8C637DA54Q39449040-461355BE-5E2F-4414-A1E1-5D687EC4F9A1Q39652783-6464AAF1-AF16-4201-B91E-EB7719DB48EEQ39730865-2D2D1A68-EBDD-4A05-BA47-0B2F01FDD1CCQ40882541-2D891C90-3F38-4E29-BAAD-3076B4218F40Q41381115-13C8C111-590F-4668-8DFD-0953E52EAA3CQ42826676-F6D8B942-9630-4DBA-8AA2-967E702F21AEQ42956812-41C28854-FB28-4629-9045-0DA55A6C3644Q43141749-BAED5FA2-ACE7-4BF0-B364-4A74B0E2971DQ43183398-0F12078B-A91C-4EFE-AA52-4D0D569ADDA1Q43420011-F1A0D558-09A9-4CBC-B963-392402228FE6Q45017876-8FC48995-4214-4BE8-A775-D41FE3058C52Q45275020-56954900-CCA4-4C58-9FA0-B1F52D5F2268Q46079037-C2067B23-581D-4FE3-AFB1-B22AC23FFF51Q46381177-FB483A5A-9D49-4636-B2F5-CCC793519EC8Q53791292-70278CAE-22EC-4751-89F8-C98F3F42DA08
P2860
The past, present and future of antimycotic combination therapy.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The past, present and future of antimycotic combination therapy.
@ast
The past, present and future of antimycotic combination therapy.
@en
type
label
The past, present and future of antimycotic combination therapy.
@ast
The past, present and future of antimycotic combination therapy.
@en
prefLabel
The past, present and future of antimycotic combination therapy.
@ast
The past, present and future of antimycotic combination therapy.
@en
P2860
P1433
P1476
The past, present and future of antimycotic combination therapy.
@en
P2093
P2860
P304
P356
10.1046/J.1439-0507.1999.00475.X
P577
1999-01-01T00:00:00Z